Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

BACKGROUND: In clinical practice the gold standard method to assess BRAF status in patients with metastatic melanoma is based on molecular assays. Recently, a mutation-specific monoclonal antibody (VE1), which detects the BRAF V600E mutated protein, has been developed. With this study we aimed to co...

Descripción completa

Detalles Bibliográficos
Autores principales: Schirosi, Laura, Strippoli, Sabino, Gaudio, Francesca, Graziano, Giusi, Popescu, Ondina, Guida, Michele, Simone, Giovanni, Mangia, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116153/
https://www.ncbi.nlm.nih.gov/pubmed/27863476
http://dx.doi.org/10.1186/s12885-016-2951-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116153/
https://www.ncbi.nlm.nih.gov/pubmed/27863476
http://dx.doi.org/10.1186/s12885-016-2951-4

Ejemplares similares